Jan 25, 2019 • 9:01 am EST Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Jan 3, 2019 • 10:01 am EST Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis
Dec 18, 2018 • 8:46 am EST Corbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum
Dec 17, 2018 • 7:00 am EST Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
Nov 8, 2018 • 7:00 am EST Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Nov 6, 2018 • 8:00 am EST Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
Nov 5, 2018 • 8:00 am EST Corbus Pharmaceuticals to Announce Third Quarter 2018 Operational and Financial Results on November 8, 2018
Oct 22, 2018 • 8:00 am EDT Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
Oct 18, 2018 • 4:05 pm EDT Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis Conference